1. Home
  2. SLN vs FNLC Comparison

SLN vs FNLC Comparison

Compare SLN & FNLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$5.75

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

HOLD

Current Price

$28.00

Market Cap

306.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
FNLC
Founded
1994
1864
Country
United Kingdom
United States
Employees
116
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
236.2M
306.9M
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
SLN
FNLC
Price
$5.75
$28.00
Analyst Decision
Buy
Analyst Count
6
0
Target Price
$39.67
N/A
AVG Volume (30 Days)
168.0K
14.4K
Earning Date
01-01-0001
04-22-2026
Dividend Yield
N/A
5.24%
EPS Growth
N/A
N/A
EPS
N/A
2.16
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.11
Revenue Growth
N/A
N/A
52 Week Low
$1.97
$22.11
52 Week High
$7.78
$30.33

Technical Indicators

Market Signals
Indicator
SLN
FNLC
Relative Strength Index (RSI) 59.50 52.25
Support Level $5.07 $25.75
Resistance Level $6.10 $28.60
Average True Range (ATR) 0.49 0.77
MACD 0.16 -0.14
Stochastic Oscillator 65.37 54.34

Price Performance

Historical Comparison
SLN
FNLC

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

Share on Social Networks: